BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 23982978)

  • 1. Role of Fms-like tyrosine kinase 3 ligand as a potential biologic marker of lymphoma in primary Sjögren's syndrome.
    Tobón GJ; Saraux A; Gottenberg JE; Quartuccio L; Fabris M; Seror R; Devauchelle-Pensec V; Morel J; Rist S; Mariette X; De Vita S; Youinou P; Pers JO
    Arthritis Rheum; 2013 Dec; 65(12):3218-27. PubMed ID: 23982978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Fms-like tyrosine kinase 3 ligand, a mediator of B cell survival, is also a marker of lymphoma in primary Sjögren's syndrome.
    Tobón GJ; Renaudineau Y; Hillion S; Cornec D; Devauchelle-Pensec V; Youinou P; Pers JO
    Arthritis Rheum; 2010 Nov; 62(11):3447-56. PubMed ID: 20556820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren's syndrome.
    Ioannidis JP; Vassiliou VA; Moutsopoulos HM
    Arthritis Rheum; 2002 Mar; 46(3):741-7. PubMed ID: 11920410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjogren's syndrome.
    Ramos-Casals M; Brito-Zerón P; Yagüe J; Akasbi M; Bautista R; Ruano M; Claver G; Gil V; Font J
    Rheumatology (Oxford); 2005 Jan; 44(1):89-94. PubMed ID: 15381790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low levels of vitamin-D are associated with neuropathy and lymphoma among patients with Sjögren's syndrome.
    Agmon-Levin N; Kivity S; Tzioufas AG; López Hoyos M; Rozman B; Efes I; Shapira Y; Shamis A; Amital H; Youinou P; Shoenfeld Y
    J Autoimmun; 2012 Sep; 39(3):234-9. PubMed ID: 22835660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rates of infiltration by macrophages and dendritic cells and expression of interleukin-18 and interleukin-12 in the chronic inflammatory lesions of Sjögren's syndrome: correlation with certain features of immune hyperactivity and factors associated with high risk of lymphoma development.
    Manoussakis MN; Boiu S; Korkolopoulou P; Kapsogeorgou EK; Kavantzas N; Ziakas P; Patsouris E; Moutsopoulos HM
    Arthritis Rheum; 2007 Dec; 56(12):3977-88. PubMed ID: 18050195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study.
    Pijpe J; van Imhoff GW; Spijkervet FK; Roodenburg JL; Wolbink GJ; Mansour K; Vissink A; Kallenberg CG; Bootsma H
    Arthritis Rheum; 2005 Sep; 52(9):2740-50. PubMed ID: 16142737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. European League Against Rheumatism Sjögren's Syndrome Disease Activity Index and European League Against Rheumatism Sjögren's Syndrome Patient-Reported Index: a complete picture of primary Sjögren's syndrome patients.
    Seror R; Gottenberg JE; Devauchelle-Pensec V; Dubost JJ; Le Guern V; Hayem G; Fauchais AL; Goeb V; Hachulla E; Hatron PY; Larroche C; Morel J; Pedriger A; Puechal X; Rist S; Saraux A; Sene D; Sibilia J; Vittecoq O; Zarnitsky C; Labetoulle M; Ravaud P; Mariette X
    Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1358-64. PubMed ID: 23436737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CXCL13 and CCL11 Serum Levels and Lymphoma and Disease Activity in Primary Sjögren's Syndrome.
    Nocturne G; Seror R; Fogel O; Belkhir R; Boudaoud S; Saraux A; Larroche C; Le Guern V; Gottenberg JE; Mariette X
    Arthritis Rheumatol; 2015 Dec; 67(12):3226-33. PubMed ID: 26359802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epstein-Barr virus, methotrexate, and lymphoma in patients with rheumatoid arthritis and primary Sjögren's syndrome: case series.
    Dawson TM; Starkebaum G; Wood BL; Willkens RF; Gown AM
    J Rheumatol; 2001 Jan; 28(1):47-53. PubMed ID: 11196542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical features distinguishing lymphoma development in primary Sjögren's Syndrome--a retrospective cohort study.
    Risselada AP; Kruize AA; Bijlsma JW
    Semin Arthritis Rheum; 2013 Oct; 43(2):171-7. PubMed ID: 23664530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cryoglobulinaemia related to Sjogren's syndrome or HCV infection: differences based on the pattern of bone marrow involvement, lymphoma evolution and laboratory tests after parotidectomy.
    De Vita S; Quartuccio L; Salvin S; Corazza L; Zabotti A; Fabris M
    Rheumatology (Oxford); 2012 Apr; 51(4):627-33. PubMed ID: 22210656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk, predictors, and clinical characteristics of lymphoma development in primary Sjögren's syndrome.
    Solans-Laqué R; López-Hernandez A; Bosch-Gil JA; Palacios A; Campillo M; Vilardell-Tarres M
    Semin Arthritis Rheum; 2011 Dec; 41(3):415-23. PubMed ID: 21665245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of mucosa-associated lymphoid tissue lymphoma in Sjogren's syndrome: a retrospective clinical study.
    Pollard RP; Pijpe J; Bootsma H; Spijkervet FK; Kluin PM; Roodenburg JL; Kallenberg CG; Vissink A; van Imhoff GW
    J Rheumatol; 2011 Oct; 38(10):2198-208. PubMed ID: 21844152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BLyS upregulation in Sjogren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands.
    Quartuccio L; Salvin S; Fabris M; Maset M; Pontarini E; Isola M; De Vita S
    Rheumatology (Oxford); 2013 Feb; 52(2):276-81. PubMed ID: 22879463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sjögren's Syndrome Disease Damage Index and disease activity index: scoring systems for the assessment of disease damage and disease activity in Sjögren's syndrome, derived from an analysis of a cohort of Italian patients.
    Vitali C; Palombi G; Baldini C; Benucci M; Bombardieri S; Covelli M; Del Papa N; De Vita S; Epis O; Franceschini F; Gerli R; Govoni M; Bongi SM; Maglione W; Migliaresi S; Montecucco C; Orefice M; Priori R; Tavoni A; Valesini G
    Arthritis Rheum; 2007 Jul; 56(7):2223-31. PubMed ID: 17599741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Malignant lymphoma in primary Sjögren's syndrome: an update on the pathogenesis and treatment.
    Routsias JG; Goules JD; Charalampakis G; Tzima S; Papageorgiou A; Voulgarelis M
    Semin Arthritis Rheum; 2013 Oct; 43(2):178-86. PubMed ID: 23816048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential risk of non-Hodgkin's lymphoma in Italian patients with primary Sjögren's syndrome.
    Valesini G; Priori R; Bavoillot D; Osborn J; Danieli MG; Del Papa N; Gerli R; Pietrogrande M; Sabbadini MG; Silvestris F; Valsecchi L
    J Rheumatol; 1997 Dec; 24(12):2376-80. PubMed ID: 9415645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of patients with primary Sjögren's syndrome--outcome over 10 years using the Sjögren's Syndrome Damage Index.
    Krylova L; Isenberg D
    Rheumatology (Oxford); 2010 Aug; 49(8):1559-62. PubMed ID: 20444857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sjögren's syndrome associated with systemic lupus erythematosus: clinical and laboratory profiles and comparison with primary Sjögren's syndrome.
    Manoussakis MN; Georgopoulou C; Zintzaras E; Spyropoulou M; Stavropoulou A; Skopouli FN; Moutsopoulos HM
    Arthritis Rheum; 2004 Mar; 50(3):882-91. PubMed ID: 15022331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.